CompletedNot Applicable

GAL1704 for Cheek Augmentation and Correction of Midface Contour Deficiencies

United States270 participantsStarted 2018-10-18

Plain-language summary

An interventional study to evaluate the safety and effectiveness of GAL1704 for cheek augmentation and the correction of midface volume deficiencies by demonstrating non-inferiority in change from baseline, relative to an active comparator.

Who can participate

Age range22 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: \- Subjects assessed at baseline by the Blinded Evaluator as Grade 2, 3, or 4 on the MMVS on each side of the midface. Exclusion Criteria: \- Previous use of any HA based or collagen based biodegradable tissue augmentation therapy within 12 months prior to the baseline visit

What they're measuring

Assess Efficacy of Study Treatment Using Medicis Midface Volume Score (MMVS)

Timeframe: 12 weeks

Trial details

NCT IDNCT03700047

SponsorGalderma R&D

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2019-06-10

Results submitted2021-07-22

View on ClinicalTrials.gov More Cheek Augmentation trials